Certara, Inc. (CERT)
| Previous Close | 11.09 |
| Open | 11.03 |
| Bid | 10.96 x 100 |
| Ask | 10.98 x 100 |
| Day's Range | 10.88 - 11.07 |
| 52 Week Range | 10.35 - 19.87 |
| Volume | |
| Avg. Volume | 1,091,562 |
| Market Cap | 1.765B |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.50 |
GlobeNewswireCertara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for
Simply Wall St.High Growth Tech Stocks To Watch In September 2024
In the last week, the market has stayed flat, but it is up 32% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions becomes crucial for investors looking to maximize their returns.
- GlobeNewswire
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisionsRADNOR, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announces the celebration of the 25th anniversary of the Simcyp® Consortium. The Simcyp Consortium has become a global authority on mechanistic physiolo
